Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 8 of 8 entries
View as:

To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD)

Phase: N/A Priority: Normal
NCT ID: NCT06888492 Org: User:
Start: 03/28/25 End: 04/30/26 Due: 04/30/27

A Study of EXG102-031 in Participants With wAMD

Phase: N/A Priority: Normal
NCT ID: NCT06183814 Org: User:
Start: 10/12/23 End: 12/31/25 Due: 12/31/26

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1

Phase: N/A Priority: Normal
NCT ID: NCT05614531 Org: User:
Start: 02/16/23 End: 08/31/25 Due: 08/31/26

The Safety and Efficacy of Intravenous EXG110 in Patients With Fabry Disease

Phase: N/A Priority: Normal
NCT ID: NCT06819514 Org: User:
Start: 03/01/25 End: 03/15/28 Due: 03/15/29

A Long-term Follow-up Study Evaluating Intravenous Injection of EXG001-307 in Patients With Type 1 SMA

Phase: N/A Priority: Normal
NCT ID: NCT06588803 Org: User:
Start: 03/31/25 End: 12/31/30 Due: 12/31/31

Clinical Trial to Evaluate the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy Type I

Phase: N/A Priority: Normal
NCT ID: NCT06576388 Org: User:
Start: 01/21/22 End: 01/21/24 Due: 01/21/25

A Long-term Follow up Study of EXG102-031 in Participants With wAMD

Phase: N/A Priority: Normal
NCT ID: NCT06859515 Org: User:
Start: 03/15/25 End: 12/01/30 Due: 12/01/31

Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy

Phase: N/A Priority: Normal
NCT ID: NCT06888661 Org: User:
Start: 03/10/25 End: 12/30/26 Due: 12/30/27